Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

BACKGROUND: Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced non‐small cell lung carcinoma (NSCLC) and positive programmed cell death ligand 1 (PD‐L1). However, no direct comparison da...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Transl Med
Main Authors: Zhou, Yixin, Zhang, Yaqiong, Guo, Guifang, Cai, Xiuyu, Yu, Hui, Cai, Yanyu, Zhang, Bei, Hong, Shaodong, Zhang, Li
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7240850/
https://ncbi.nlm.nih.gov/pubmed/32508007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.14
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares